Latest Breaking News On - Patients with treatment naive chronic lymphocytic - Page 1 : comparemela.com

Constantine S. Tam, MD, MBBS, presents the biomarker subgroup analysis from the phase 3 SEQUOIA study investigating zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p).

Constantines tamEuropean research initiativeBroad superiorityZanubrutinib over bendamustineRituximab across multiple high risk factorsBiomarker subgroup analysisPatients with treatment naive chronic lymphocyticSmall lymphocytic lymphoma withoutClinical practiceSequoia studyChronic lymphocytic leukemiaDeletion 17p17p deletionNext generation sequencing